The second talk in our Psychedelics mini-series will examine how the endocannabinoid system (ECS) is involved in regulating and balancing various physiological actions in the body. Alterations in components of ECS signaling have been associated with various conditions. For example, an underactive ECS is seen in post-traumatic stress disorder (PTSD) and migraine, whereas an overactive ECS is associated with metabolic disorders. Accumulating evidence has shown that targeting the ECS may be beneficial for many pathophysiological conditions. The potential role of non-psychoactive naturally occurring modulators of the ECS including phytocannabinoids, terpenes, and palmitoylethanolamide (PEA) will be discussed.
Speaker Bio: Dr. Karimian-Azari holds her PhD from the physiology and behavior group at the Institute of Food, Nutrition, and Health at Swiss Federal Institute of Technology (ETH-Zurich), with a focus on metabolism and the control of eating. During her postdoctoral work at Sanford-Burnham Medical Discovery Institute, she conducted her research on the intestinal nutrient absorption, gut endocrine signaling, and glucose metabolism with a focus on taste receptors. She is currently therapeutic platform lead within R&D department at Metagenics.
*Certified by the WANP for 1 Category 1 continuing education credit (including 1 Pharmacology credit) for Washington NDs*
(Originally presented on October 12, 2020)